ImmunityBio Reports 700% ANKTIVA Revenue Growth and Expanded Global Approvals in 2025 Annual Report

summarizeSummary

ImmunityBio's 2025 annual report highlights significant commercial success for ANKTIVA with 700% year-over-year revenue growth and expanded global regulatory approvals, alongside a reduced net loss and improved operating cash flow, despite ongoing financial and regulatory challenges.

check_boxKey Events

• Strong ANKTIVA Commercial Performance

  Net product revenue for ANKTIVA surged to $113 million in 2025, marking a 700% year-over-year increase following its May 2024 commercial launch.

• Expanded Global Regulatory Approvals

  ANKTIVA received conditional marketing authorization in the EU (February 2026) and full approval in Saudi Arabia (January 2026), expanding its market to 33 countries for BCG-unresponsive NMIBC. It also secured the first IL-15 receptor superagonist approval for lung cancer in Saudi Arabia.

• Improved Financials Amidst Losses

  The company reduced its net loss to $351.5 million in 2025 from $413.6 million in 2024, and operating cash outflow improved to $304.9 million from $391.2 million.

• Ongoing Regulatory and Legal Challenges

  ImmunityBio is addressing an FDA Refuse to File (RTF) letter for its sBLA in papillary NMIBC and previously received FDA untitled letters regarding promotional claims. An arbitration related to CVRs from the Altor acquisition is ongoing, seeking approximately $164.2 million plus interest.

auto_awesomeAnalysis

ImmunityBio's 2025 annual report demonstrates significant progress in its transition to a commercial-stage biotechnology company, driven by the strong launch and rapid global expansion of its lead product, ANKTIVA. The 700% year-over-year revenue growth and approvals in key markets like the EU and Saudi Arabia are critical milestones, validating the product's potential and expanding its addressable market. While the company continues to report substantial net losses and acknowledges "substantial doubt" about its going concern status, the reduction in net loss and improved operating cash flow, coupled with management's confidence in securing additional funding (including from affiliated entities), indicate a positive financial trajectory. Investors should monitor the ongoing regulatory discussions with the FDA regarding the sBLA for papillary NMIBC and the outcome of the CVR arbitration, as these represent potential headwinds. However, the commercial momentum and strategic financial maneuvers provide a more optimistic outlook for the company's ability to fund its extensive pipeline and operations.